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Abstract: Systemic lupus erythematosus (SLE) is a clinically and genetically heterogeneous autoimmune
disease. The etiology of lupus and the contribution of genetic, environmental, infectious and hormonal
factors to this phenotype have yet to be elucidated. The most straightforward approach to unravel the
molecular pathogenesis of lupus may rely on studies of patients who present with early-onset severe
phenotypes. Typically, they have at least one of the following clinical features: childhood onset of
severe disease (<5 years), parental consanguinity, and presence of family history for autoimmune
diseases in a first-degree relative. These patients account for a small proportion of patients with lupus
but they inform considerable knowledge about cellular pathways contributing to this inflammatory
phenotype. In recent years with the aid of new sequencing technologies, novel or rare pathogenic
variants have been reported in over 30 genes predisposing to SLE and SLE-like diseases. Future studies
will likely discover many more genes with private variants associated to lupus-like phenotypes.
In addition, genome-wide association studies (GWAS) have identified a number of common alleles
(SNPs), which increase the risk of developing lupus in adult age. Discovery of a possible shared
immune pathway in SLE patients, either with rare or common variants, can provide important
clues to better understand this complex disorder, it’s prognosis and can help guide new therapeutic
approaches. The aim of this review is to summarize the current knowledge of the clinical presentation,
genetic diagnosis and mechanisms of disease in patents with lupus and lupus-related phenotypes.
Keywords: systemic lupus erythematosus; lupus; SLE; genetic; monogenic; mendelian; familial;
complement deficiency; interferonopathies; interferon-stimulated genes (ISGs)
1. Introduction
Systemic lupus erythematosus (SLE; OMIM 152700) is a complex autoimmune disease not only
from a clinical standpoint but also from genetic and immunological aspects of the disease. Multiple
studies have shown that loss of immune tolerance to cell surface and nuclear antigens contribute to
this disease, however, the underlying etiology and triggering event for impaired immune tolerance
remain elusive.
Up to 100 susceptibility loci for polygenic, multifactorial SLE and more than 30 genes causing the
monogenic form of SLE and SLE-like phenotypes have been described, yet they capture only a small
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proportion of heritability to lupus and other autoimmune diseases (Table 1) [1–6]. Discovery of novel
or rare disease-causing gene variants in patients with early-onset SLE phenotype has had a significant
contribution to the unraveling of molecular pathways involved in the disease pathogenesis [7–9].
The term monogenic lupus has been introduced to denote SLE patients who carry high-penetrance
either dominantly or recessively inherited pathogenic variants in a single gene. Among these rare forms
of the disease, mutations in the genes encoding for complement pathway are the first and foremost
described. Apart from the complement deficiencies, the vast majority of the single gene defects
that lead to monogenic lupus are categorized under the umbrella of type I interferonopathies [8,9].
This term is broadly defined but essentially indicates persistent upregulation of type I interferon
(IFN) signaling as measured by high expression of interferon-stimulated genes (ISGs). Whether this
signature is causal to the pathology or represents an association remains unclear and mechanisms
leading to the upregulation of interferon signaling are yet to be clarified. The close association between
SLE and up-regulated type I IFN signaling has been a well-known entity for a long time [10]. High
expression of ISGs (interferon-stimulated genes; also called interferon signature), which is accepted
as an indirect and feasible evidence of excessive type 1 IFN production, was invariably found to
be higher in blood samples of lupus patients [11]. Type I interferonopathies are considered in the
spectrum of autoinflammatory and autoimmune diseases in which the engagement of adaptive and
innate immune cells occurs (Figure 1). As a result, patients may exhibit the clinical and molecular
features of autoimmune and autoinflammatory disease [12–14]. Although, the intricate connections
of innate and adaptive immune systems have been studied both in humans and mice, they are still
poorly understood.
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Figure 1. Diagram of genes associated with monogenic systemic lupus erythematosus (SLE) and SLE-
like features. The depicted genes carry novel or rare pathogenic variants that have been described in 
patients presenting with lupus or have either clinical or biochemical features of autoimmunity. The 
inner diagram includes genes associated with an upregulated type I interferon and most of these 
diseases are considered primary interferonopathies. The outer diagram depicts the genes that, when 
mutated, are associated with a spectrum of immune dysregulations and patients can manifest both 
features of immunodeficiency and autoimmunity. Typically, the autoimmune phenotype is milder 
than in patients with primary interferonopathies and there is no evidence of enhanced type I 
interferon signaling. 
Table 1. Genes linked to monogenic lupus and monogenic immune dysregulations with features of 
autoimmunity. 
Pathway Gene Inheritance Disease Reference 
Complement 
pathway 
C1q AR SLE, AGS [18–24] 
C1r/C1s AD [7,25,26] 
C2 AR [27] 
C4 AR [28–32] 
Type I IFN 
pathway 
DNASE1 AD HUV, lupus [33–35] 
DNASE2 AR [36,37] 
DNASE1L3 AR [38,39] 
TREX1 AD/AR AGS, SLE [40–47] 
IFIH1 AD SLE, AGS, FCL, Singleton-
Merton syndrome 
[48–51] 
DDX58 AD SMS, glaucoma and skeletal 
abnormalities 
[52,53] 
Figure 1. Diagram of gen s associated with monogenic systemic lupus rythematosus (SLE) and
SLE-like features. The depicted genes carry novel or rare pathogenic variants that have been described in
patients presenting with lupus or have either clinical or biochemical features of autoimmunity. The inner
diagram includes g nes sociated with an upreg lated type I interferon nd most of these diseases
are considered primary interferonopathies. The outer diagram depicts the genes that, when mutated,
are associated with a spectrum of immune dysregulations and patients can manifest both features of
immunodeficiency and autoimmunity. Typically, the autoimmune phenotype is milder than in patients
with primary interferonopathies and there is no evidence of enhanced type I interferon signaling.
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The wide range of molecular pathways identified by genetic studies disclose the complexity
of hereditary predisposition to lupus. Clinical variability of the disease is further influenced by a
number of contributing elements including genetic modifiers, epigenetic and environmental factors.
These factors create a barrier to establishing early diagnosis and carrying out appropriate treatment
and effective disease monitoring. Furthering our understanding of the genetic causes of lupus and
molecular diagnosis are the major steps towards precision medicine in SLE.
2. Genes and Molecular Pathways Associated with Lupus Phenotype
The concordance rate for SLE in monozygotic twins was found to be 24%, compared to only 2% in
dizygotic twins [15]. Familial aggregation of various autoimmune diseases including SLE have been
demonstrated in a large cohort of Latin American SLE patients and in other founder populations [16].
Compared to adult-onset SLE, patients with childhood-onset SLE are more likely to carry novel/rare
high-penetrance variants associated with mendelian lupus or may have a burden of low-penetrance
common SLE susceptibility alleles that can have additive effects [7,17]. The high degree of concordance
rate among monozygotic twins, substantial familial aggregation and discovery of numerous common
and rare variants are all supportive of a strong genetic background for SLE.
It was previously thought that the relevant genetic variants and the causal molecular pathway involved
in lupus were associated with distinct clinical presentations. This simplification greatly underestimated
the biological complexity of this disease. Mutations within the same gene and identical gene variants have
been associated with different clinical phenotypes including lupus, type I interferonopathy or familial
chilblain lupus (FCL) (chilblain lupus 1: OMIM 610448; chilblain lupus 2: OMIM614415). Conversely, a
significant clinical and molecular overlap has been observed between patients with mutations in different
genes. In this review, the genes involved in monogenic lupus will be categorized in four main groups
based on the relevant pathways which they are associated with: complement pathway, type I IFN pathway,
self-tolerance pathway, and other yet uncharacterized pathways (Table 1).
Table 1. Genes linked to monogenic lupus and monogenic immune dysregulations with features of autoimmunity.
















TREX1 AD/AR AGS, SLE [40–47]
IFIH1 AD SLE, AGS, FCL, Singleton-Mertonsyndrome [48–51]
DDX58 AD SMS, glaucoma and skeletalabnormalities [52,53]
ISG15 AR basal ganglia calcification, AGS,
pseudo-TORCH syndrome, MSMD, SLE [54–57]USP18 AR
SAMHD1 AD AGS, SLE, FCL, CLL, deformingarthropathy and recurrent oral ulcers [58–61]
OTUD1 AR SLE, autoimmune disease [62]
ACP5 AD/AR SPENCD, SLE, skeletal abnormalities [63–66]
TMEM173 AD SAVI, SLE, FCL, SCID [67–70]
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Table 1. Cont.
Pathway Gene Inheritance Disease Reference
Self-tolerance
pathway









AD NS, SLE [80–91]
Other
pathways
RAG1 AR SLE, SCID [92,93]
RAG2 AD
FAS/FASL AD SLE, ALPS [94,95]
TNFAIP3 AD SLE, ALPS, BD-like [96–100]
ADA2 AR SLE, DADA2 [101,102]
IKZF1 AD SLE, ITP, CVID [103–105]
SLE: systemic lupus erythematosus, SMS; Singleton–Merten syndrome, HUV: hypocomplementemic urticarial
vasculitis, AGS: Aicardi-Goutières syndrome, FCL: familial chilblain lupus, CLL: chronic lymphocytic leukemia,
MSMD: mendelian susceptibility to mycobacterial disease, SPENCD: spondyloenchondrodysplasia, SAVI:
STING-associated vasculopathy with onset in infancy, SCID: severe combined immune deficiency, ALPS: autoimmune
lymphoproliferative syndrome, NS: Noonan-related syndrome, DADA2: deficiency of ADA2, BD: Behçet’s disease,
ITP: immune thrombocytopenic purpura, CVID: common variant immunodeficiency disease, AR: autosomal
recessive, AD: autosomal dominant.
2.1. Complement Pathway
Genetic defects in the complement system are the first and the most frequently described category
in the field of monogenic lupus (Table 1). The complement system comprises more than 30 proteins
which make up important components of the innate immunity [106]. Complement is crucial for defense
against pathogens and for clearance of autologous immune complexes and apoptotic cells. When the
complement system is hyperactivated, it drives a severe inflammatory response in numerous organs,
particularly in the kidneys. Paradoxically, a complement genetic deficiency or acquired deficiency due
to the presence of autoantibodies directed against complement proteins are also linked to SLE.
Complement components are activated by several sequential enzymatic processes through one
of the three pathways: classical, alternative or lectin. Deficiencies of proteins in the early steps of
the complement pathway are generally associated with both autoimmune diseases and infections.
Conversely, deficiencies in late complement proteins are merely associated with an increase in infection
rates [18,106].
Defects in early complement proteins (C1q, C1r/C1s, C2 and C4) are thought to trigger autoimmunity
as a consequence of impaired opsonization, which is critical for removal of immune complexes and
apoptotic bodies by phagocytes, and as result of B lymphocyte activation. The accumulation of autoantigens
leads to activation of immune responses and systemic inflammation. In addition, presentation of immune
complexes in a complement-dependent manner to the B lymphocytes by the complement receptors
CR1(CD35) and CR2 (CD21) on dendritic cells are essential for maintenance and activation of memory B
cells [107].
C1q has additional functions that go beyond immune surveillance, tolerance and clearance of
self and non-self-antigens. C1q inhibits type I IFN and other cytokines production either directly or
via interaction with leucocyte associated Ig-like receptor (LAIR)1 on dendritic cells and by inhibition
of TLR7 and TLR9 mediated IFN-α production. The main producers of type I IFN are plasmacytoid
dendritic cells, while the uptake of immune complexes coated with C1q protein is carried out principally
by monocytes [19]. In addition to lupus, infantile-onset Aicardi-Goutières syndrome (AGS) phenotype
was also observed in a patient with C1q deficiency [20,21].
Similarly to other monogenic forms of SLE, inherited complement deficiencies may present with
early-onset lupus-like manifestations and without gender predilection that is observed in patients with
adult-onset lupus [7,25,108]. A systematic analysis of reported cases showed that the strength of the
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association between complement deficiency and lupus depends on the position of the missing protein
in the cascade (C1 > C4 > C2) [109]. The frequency of SLE or SLE-like phenotype is approximately
90% in patients with C1q deficiency, 65% in C1r/C1s deficiency, 75% in C4 deficiency and 10% in
C2 deficiency [7,22–24,26,27,110–114]. Compared to the polygenic form of SLE, more severe disease
course, frequent cutaneous manifestations and a high mortality rate are noted [7,12,18,22–26,114,115].
The association of C1q and C1r deficiency with an upregulation in type I IFN signaling may explain
the increased prevalence of SLE in early complement deficient patients [18,112]. The phenotype of
patients with early complement deficiencies can also be more severe due to recurrent infections.
Among the complement proteins there is a unique gene dosage phenomenon for the C4 gene that
is associated with predisposition to SLE. C4 is encoded by two different genes, C4A and C4B, with a
considerable gene copy number variations. Variation in C4 copy numbers is related to earlier onset
and more severe disease course. Although, C4 deficiency is strongly associated with lupus phenotype,
complete genetic deficiency is rare. In contrast, the copy number variation (CNV) of C4 genes (C4A and
C4B), which ranges from two to eight copies, is recognized as a crucial factor in prediction of the risk
for juvenile-onset SLE [28,29]. Recent population studies consistently showed that the higher the copy
number of C4 genes, the lower the risk of non-mendelian SLE, and vice versa [29–32]. High numbers
of auto-reactive B cells, glomerulonephritis and increased levels of autoantibodies were detected in
mice with defective C4 genes [116].
2.2. Type I Interferon (IFN) Pathway
The upregulation in type 1 IFN pathway can occur through different mechanisms: defect in
nucleases activity (TREX1, SAMHD1, ADAR1, RNases, DNases), defect in a negative regulator of IFN
signaling (ISG15, USP18) and by constitutive activation of an innate immune sensors (MDA5, RIG-I,
STING) (Table 1) (Figure 1). Increased expression of interferon-stimulated genes (ISGs) is the hallmark
of these diseases. Why some interferonopathies lead to systemic inflammation/autoimmunity while
other present with neurological disease remains unclear.
These discoveries were fundamental as they suggested use of new therapies targeting the interferon
pathway. Treatment of patients with the anti-IFN-α therapies has been shown to suppress the interferon
signature and disease activity [117–121]. There is also a number of undergoing clinical trials with
janus kinase (JAK) inhibitors in patients with SLE that can be found at the ClinicalTrials.gov website
(NCT03843125, NCT03978520, NCT03134222, NCT02535689, NCT03288324).
2.2.1. Deoxyribonuclease Deficiencies
Deoxyribonucleases (DNase) are a group of enzymes that catalyze the degradation of DNA molecules
and thus serve to prevent recognition of self-DNA. To date, four different DNases have been linked to
monogenic lupus: DNase I, DNase1L3, DNase II and TREX1. DNase I is a major serum endonuclease that
degrades extracellular dsDNA from dying cells. DNase II is a major lysosomal endonuclease that plays a
pivotal role in the degradation of exogenous DNA encountered by endocytosis. Deoxyribonuclease 1
like 3 (DNase1L3) is homologous with DNase I and is presumed to play a role in clearance of neutrophil
extracellular traps (NETs) [122].
Recessively inherited loss of function rare/novel mutations in DNASE I, DNASE II and DNASE1L3
genes are associated with a loss of DNase endonuclease activity [33,34,36,38,110,112]. As result, the
accumulation of nucleic acid leads to activation of DNA sensors and type I interferon signaling
pathway, although an interferon signature has been shown only in patients with DNASE II deficiency.
Genetic defects in these three genes have been described as the cause of a mendelian and early-onset
lupus that is characterized by presence of antinuclear and anti-double-stranded deoxyribonucleic acid
(ANA and anti-dsDNA) antibodies and hypocomplementemia [33,34,36,38] (Table 1). Other features of
autoimmunity has been noted in these patients including Sjogren syndrome (ref 48). Observation of an
SLE-like phenotype in Dnase1 and Dnase1L3-deficient mice was supportive of these reports [123,124].
Interestingly, Dnase2 deficient mice were embryonic lethal owing to severe anemia [37]. DNASE1L3
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mutations were identified in two unrelated Turkish families with five affected children presenting
with hypocomplementemic urticarial vasculitis (HUV) [39]. It is noteworthy that HUV and SLE share
many clinical manifestations. In Korean and Spanish cohort studies, a particular single nucleotide
polymorphism (SNP) in exon 8 of DNASE1, p. Gln244Arg (rs1053874), was shown to be associated with
production of autoantibodies and increased SLE susceptibility. However, this SNP did not correlate
with DNase activity in sera of SLE patients and controls [35,125]. Furthermore, the upregulation
in interferon gene expression signature has not been demonstrated in any of these patients. Thus,
decreased DNase activity due either to the presence of circulation inhibitory factors or loss of function
mutations is linked to many autoimmune phenotypes including lupus.
TREX1 (also called DNase III) is major mammalian 3′-5′ DNA endonuclease that resides in the
cytosol and acts both on single and double stranded DNA. TREX1 cleaves mismatched and modified
nucleotides from DNA 3′ end and degrades DNA derived from retroviruses and retrotransposons [126].
Recognition of these elevated levels of nucleic acids by a cytosolic sensor cyclic GMP-AMP (cGAMP)
synthase (cGAS) induces the production of type I IFNs via the stimulator of IFN genes protein (STING)
and when excessive can trigger autoimmunity [71,127,128]. Crossing of Trex1-deficient mice with mice
heterozygous for mutation in cGAS or STING ameliorates the phenotype [40,129,130].
Heterozygous or recessive loss-of-function mutations in the TREX1 gene lead to dysfunctional
exonuclease activity [8]. Although most patients carry biallelic pathogenic variants in this gene, some
mutations, p.Asp200Asn (D200N) and p.Asp18Asn (D18N), are linked to a dominant phenotype.
The difference in inheritance type is related to the magnitude of effect of the disease-causing variants
on the protein DNase degradation activity. The dominantly inherited mutations affect the catalytic site
and DNA binding proficiency of this enzyme [41].
Variable disease expressivity and surprisingly reduced penetrance have been reported in these
patients. Cold-induced skin lesions on distal extremities, high titers of multiple autoantibodies
and hypergammaglobulinemia are general characteristics of TREX1 deficiency. In addition to these
clinical features, infantile-onset neurologic manifestations including encephalopathy with basal ganglia
calcifications and white matter lesions, cerebrospinal lymphocytosis mimicking congenital virus
infections, which are hallmarks of AGS, hav been also reported in some cases. Progressive neurologic
involvement eventually leads to severe physical and intellectual disability in the vast majority of
patients [110,112].
TREX1 mutations are detected in about 25% of AGS patients, and in up to 2% of patients with
lupus. Among the patients with a TREX1 mutation, 60% of subjects are documented to have at least
one of the following lupus features: antibodies to extractable nuclear antigens (ENA), ANA and
anti-dsDNA, thrombocytopenia, leukopenia, skin lesions, oral ulcers and arthritis [127]. Over time,
with the addition of systemic features to the limited cutaneous manifestations of FCL, 18% of the
FCL cases have eventually evolved into SLE [42,112]. Targeted TREX1 gene analysis in large adult
SLE cohorts yielded new cases who carry heterozygous mutations predominantly clustered in the
C-terminal protein domain [43–45]. Rare variants in the TREX1 gene were also observed in other
autoimmune diseases including Sjogren’s syndrome and systemic sclerosis [46].
Genetic counseling can be challenging. In one family, a child with severe neurological features
resembling AGS inherited the p.Asp18Asn mutation from her mildly affected mother, while other
family members who were carriers for this mutation mostly presented with chilblains [47].
2.2.2. SAMHD1
Recessively inherited loss-of-function mutations in SAM (sterile alpha motif) domain and HD
(phosphohydrolases named HD after the conserved doublet of predicted catalytic residues) Domain-
containing protein 1 (encoded by SAMHD1 gene) result in increased levels of deoxyribonucleoside
triphosphates (dNTPs) by inhibiting the degradation of these DNA precursors [58,110,112]. The excessive
presence of dNTP pools, as a result of SAMHD1 mutations, leads to DNA damage, cell cycle arrest and cell
death by impairing DNA replication and repair mechanisms. Acquired (somatic) SAMHD1 mutations
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are found in patients with chronic lymphocytic leukemia, CLL (OMIM 151400) [59]. Furthermore, accrual
of cytosolic dNTPs is sensed as danger molecules, which in turn stimulates type I IFN pathway [58].
Pathogenic variants in the SAMHD1 gene have been implicated in the pathogenesis of three different
clinical disorders including AGS, SLE and FCL, similar to TREX1 mutations [60,71,131,132]. A distinct
phenotype with deforming arthropathy and recurrent oral ulcers in addition to the classical neurologic
and skin manifestations, has also been described [61].
2.2.3. Cytosolic RNA Nucleic Acid Degradation/Editing Pathways
Biallelic loss of function mutations in ribonucleases RNASEH2A, RNASEH2B, RNASEH2C,
and RNA-specific adenosine deaminase 1 (ADAR1) cause spectrum of phenotypes with varying
degrees of severity: mildest familial chilblain lupus (FCL), moderate severity systemic lupus, and
most severe Aicardi–Goutières syndrome (AGS1-7: OMIM 225750, 610181, 610329, 610333, 612952,
615010, 615846) [9,71,72,110,112,113]. Their deficiency result in accumulation of RNA/DNA hybrids or
RNA molecules that ultimately leads to an excessive type I IFN signaling. Occasionally, the disease
with a uniform phenotype due to the aforementioned mutations evolves over time into one with
overlapping features of AGS, FCL and SLE [42,127,128]. For instance, in an Italian study, more than
half of the patients with genetically confirmed AGS were found to have autoantibodies despite lack of
any autoimmunity related clinical manifestations [133]. Presence of autoantibodies against the nuclear
antigens and the endothelial cells and astrocytes in the brain was demonstrated in another multi-center
study [134].
2.2.4. Nucleic Acid Sensing Pathways
Melanoma differentiation-associated protein 5 (MDA5) and retinoic acid-inducible gene (RIG-I)
are cytoplasmic double stranded ribonucleic acid (ds-RNA) sensors that play an essential role in
the triggering of antiviral responses [135]. Their expression is typically low in resting cells and is
greatly increased upon exposure to viral infection. Autoactivation of these sensors due to pathogenic
mutations in the helicase domains of respective proteins leads to various autoimmune diseases.
Heterozygous missense gain of function mutations in the IFIH1 gene (encoding MDA5), account
for several disease phenotypes including SLE, AGS, FCL and Singleton–Merten syndrome (SMS;
OMIM 182250) [48–50,71]. Constitutive activation of MDA5 receptor leads to excessive type I IFN
signaling as demonstrated by high expression of ISGs [49,52]. Reduced penetrance mutations have
been reported in some families, which suggest that other factors such as viral exposure contribute
to the disease expression [51]. Whole-exome sequencing (WES) revealed a de novo IFIH1 mutation,
p.Arg779His, in a 16-year-old Belgian girl presenting with severe early-onset SLE, immunoglobulin (Ig)
A deficiency and lower limb spasticity [50]. Similarly, severe lupus-like disease including nephritis,
high ANA and anti-ds DNA autoantibodies, developed in mice with a gain of function mutation in
MDA5. Sustained upregulation of IFN and ISGs in the activated dendritic cells and macrophages
elicited antibody production by B cells and plasma cells [52]. The association of a SNP in IFIH1,
p.Ala946Thr (rs1990760), with anti-ds DNA antibodies was shown in a cohort of 563 SLE patients
and correlated with increased ISG expression in an anti-ds DNA positive subgroup [136]. This IFIH1
variant was demonstrated to increase susceptibility not only to SLE but also to type I diabetes mellitus,
multiple sclerosis and rheumatoid arthritis in a meta-analysis [137].
Heterozygous mutations in RIG-I (encoded by the DDX58 gene) have been identified in a family
with atypical SMS and in patients with glaucoma and skeletal abnormalities [53]. Both mutations
lead to increased IFN activity. Why patients with SMS in contrast to patients with other types of
interferonopathies develop skeletal and dental abnormalities and aortic calcifications remains unclear.
Rig-I deficient mice were viable and developed colitis-like phenotype due to T cell activation, which
shows that RIG-I has a function in maintenance of T cell homeostasis [138].
Another type I interferonopathy that can manifest with SLE-like phenotype is STING-associated
vasculopathy with onset in infancy (SAVI) (OMIM 615934) [67,129]. The STING, a transmembrane
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protein residing on endoplasmic reticulum, is an essential and common sensor of self-DNA molecules.
In normal circumstances, activation of STING by its ligand, cGAMP, leads to expression of type I
IFN through downstream pathways including a protein kinase TBK1 and IRF-3 [139]. Heterozygous
pathogenic missense mutations in TMEM173, which encodes STING, result in constitutively active
STING [67,129]. Mutations that reside in exon 5, which encodes a highly conserved dimerization
domain, act by reinforcing the stability of STING dimers and lead to ligand-independent activation of the
TBK/IRF3 pathway. Patients with a most severe phenotype described as SAVI present with early-onset
systemic inflammation, interstitial lung disease, and cutaneous manifestations including malar rash,
erythematous plaques and nodules, cold-induced chilblain-like lesions that can evolve into ulcers and
peripheral amputations [129]. Anti-phospholipid antibodies were present in five out of six patients and
low-titer ANA was detected in half of the children. Although the aforementioned features mimic SLE,
the authors reported that none of the subjects met the SLE criteria [129]. Interestingly, mice who carry one
of the SAVI-associated mutations developed features of severe combined immunodeficiency [68,140].
STING-associated diseases have variable expressivity. In a family with four affected patients, one
had been diagnosed with infantile-onset SLE, while the other three family members had a disease
onset after 12 years of age [67]. Classical SAVI phenotype including recurrent fever episodes, malar
rash and interstitial lung disease were observed in three family members. However, a 65-year-old
family member exhibited a significantly different phenotype with marked failure to thrive and articular
manifestations. All subjects had elevated acute phase reactants and were positive for rheumatoid
factor (RF) and ANA with various titers, whereas only the index case had positive anti-dsDNA. More
recently, a heterozygous TMEM173 mutation, p.Gly166Glu, was identified in a Greek family with five
members affected with familial chilblain lupus (FCL) [69]. Interestingly, this mutation resides in the
dimerization domain of STING like SAVI-associated causal variants, however other than cold-induced
chilblain lesions, none of the patients had fevers and lung disease. Similar to previous case-series,
ANA positivity was detected in four out of five family members [69]. Some patients presented with
lymphopenia of T and NK cells and mild immunodeficiency, which is consistent with the role of
STING in lymphoid development [70]. Such variability in the disease expression might be explained
by presence of modifying alleles in TMEM173 and other genes.
2.3. Negative Regulators of Type I Interferon Signaling Pathway
2.3.1. ISG15 and USP18
The ISG15 is a type I IFN inducible ubiquitin-like protein that stabilizes the levels of ubiquitin-specific
peptidase 18 (USP18), a potent negative regulator of IFN-α/β signaling [141]. In the absence of ISG15,
USP18 is degraded via a proteasome, which permits signaling through the IFN alpha receptor (IFNAR)
and leads to increased antiviral activity [54,55,141]. Biallelic recessively inherited mutations in these
two genes, ISG15 and USP18, result in enhanced type I IFN response (Table 1, Figure 1). Patients present
with a wide spectrum of neurological and immunological manifestations, including basal ganglia
calcification, AGS, pseudo-TORCH syndrome (OMIM 617397), seizures and mendelian susceptibility
to mycobacterial disease (MSMD) (OMIM 209950) [54,55,141]. The MSMD immunodeficiency is
characterized by susceptibility to infection with weakly virulent mycobacteria as a result of insufficient
ISG15-dependent IFN-γ production [55,141]. Although higher autoantibody levels were identified in
patients with ISG-15 deficiency compared to the age-matched controls, there are no reports of lupus
patient carrying ISG15 or USP18 mutations [55]. However, significantly higher levels of ISG15 in SLE
patients compared to healthy controls and other disease controls suggested that ISG15 could be a
possible diagnostic marker for SLE and other interferonopathies [56,57]. Moreover, the ISG15 levels
were found to correlate with disease activity in SLE patients [57].
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2.3.2. OTUD1
OTUD1 gene encodes a widely expressed deubiquitinase that plays a role in the regulation of IRF3
transcriptional activity. OTUD1 interacts with IRF3 to remove the K63-linked poly-ubiquitin chains
on IRF3 and to suppress the interferon activity. Patients with loss-of-function missense mutations in
OTUD1 present with an autoimmune disease, including some patients diagnosed with SLE [62]. These
mutations may abolish the interaction with IRF3 or may act by reducing OTUD1 deubiquitinase activity.
2.3.3. ACP5
Spondyloenchondrodysplasia (SPENCD; OMIM 607944) is a disorder very similar to the AGS
with regard to neurologic manifestations (intracranial calcifications, spasticity) and autoimmunity
(frequent SLE manifestations). However, skeletal abnormalities such as short stature, platyspondyly
and enchondromatosis are unique features related to SPENCD [63–65,110,112]. Autosomal recessive
mutations in the ACP5 gene results in a deficiency of tartrate-resistant acid phosphatase (TRAP) enzyme,
which is expressed in osteoclasts and myeloid cells. TRAP is required for processing and/or degradation
of osteopontin (OPN) in plasmacytoid dendritic cells (pDCs) by catalyzing the dephosphorylation of
OPN. Increased activity of OPN, when in a phosphorylated state, continuously stimulates the TLR9
signaling pathway. This activation results in nuclear translocation of IRF7 and NFkB, which in turn
increases the expression of type I IFN, IL-6 and TNF [66]. Increased OPN levels seem to trigger type I
IFN production and autoimmunity and are responsible for the skeletal dysplasia [63–66]. Virtually, all
SPENCD patients were found to be positive for anti-dsDNA and/or ANA autoantibodies, whereas only
half of them met the ACR 1997 criteria for SLE [64,65]. Heterozygous missense ACP5 variants were
detected with an increased frequency in a cohort of non-mendelian SLE, suggesting that the TRAP
deficiency may increase the susceptibility to SLE [66].
2.4. Self-Tolerance Pathway
B lymphocytes play a key role in development of autoimmunity more than other cell types of
the innate and adaptive immune system. Failure in the elimination of self-reactive cells during the
development process of B cells, also called inadequate negative selection, may lead to loss of tolerance
and development of autoimmunity (Table 1, Figure 1). Autoimmune processes can be further halted by
deleting the B lymphocytes with B cell receptors (BCR) recognizing self-antigens at various checkpoints.
2.4.1. PRKCD
Protein kinase C-δ (PKC-δ) encoded by PRKCD gene, has been implicated in the regulation
of apoptosis, survival and proliferation of lymphocytes [142]. Lupus-like manifestations including
glomerulonephritis, lymphadenopathy, splenomegaly and positive-titers of autoantibodies developed
in PRKCD knockout mice [143]. PKCδ-deficient mice showed an impaired negative selection of
self-reactive B cells, which leads to uncontrolled B cell proliferation in peripheral lymphoid tissues.
The hyperproliferative phenotype was B-cell autonomous. Homozygous missense mutation in
PRKCD was identified in three siblings from consanguineous parents, all of whom met the ACR
criteria for SLE [73]. Decreased expression and enzymatic activity of PKC-δ, impaired apoptosis and
expansion of immature B cells were demonstrated. Typical cutaneous lupus rashes, lupus nephritis,
positive ANA, positive anti-ds DNA were observed in all of three patients. Lymphadenopathy,
hepatomegaly or splenomegaly, which are suggestive of a lymphoproliferative disease, were detected
in two out of three patients. Subsequently, four other children with early-onset SLE-like manifestations
including lupus-like rash, high-titers of various autoantibodies, nephritis or cytopenia were also later
described [74–76]. A lymphoproliferative disorder manifested by hepatomegaly and/or splenomegaly
and/or lymphadenopathy was observed in all of these children. An infantile-onset case with
overlapping features of primary immunodeficiency due to a B-cell deficiency and autoimmunity
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including membranous glomerulonephritis, presence of ANA, anti-ds DNA and anti-phospholipid
antibodies has been also reported [77].
2.4.2. TNFSF13B/BAFF
Overexpression of the cytokine and drug target B-cell activating factor (BAFF; encoded by
TNFSF13B) has been associated with susceptibility to SLE, multiple sclerosis and rheumatoid
arthritis. The functional causal variant denoted as BAFF-var (a combination of rs374039502 and
an insertion-deletion variant GCTGT→A [rs200748895]) has been initially identified by Genome Wide
Association study (GWAS) in the Sardinian population and recently replicated in other cohorts of
patients [78,79,144]. The BAFF-var is more frequent among Sardinians (MAF = 33%) than other
populations (Europeans MAF = 3–5%) and was shown to yield a shorter transcript that escapes
microRNA inhibition. As result there is increased production of soluble BAFF and a higher number
of B lymphocytes and immunoglobulins, predisposing to autoimmunity. High BAFF expression is
related to active disease, renal and hematological involvement in SLE patients [145].
Although belimumab, which targets BAFF, has been approved for the treatment of SLE by the
Food and Drug Administration this variant was not associated with belimumab efficacy as measured
by the primary efficacy end point SRI4, which integrates three validated lupus instruments measuring
disease activity. The study is likely underpowered to detect an association for a minor allele frequency
of 5% or less [146].
2.5. Other Pathways Associted with Susceptibility to Lupus-like Phenotypes
2.5.1. RAG1 and RAG2
Primary immunodeficiencies with autoimmune features have been increasingly recognized in the
last decade (Table 1, Figure 1). Severe combined immunodeficiency with lack of T and B lymphocytes
(SCID; OMIM 601457) is caused by recessively inherited mutations in recombinase activating gene
(RAG) 1 and 2. Patients have profound lymphopenia and diminished or absent immunoglobulins
and present with recurrent opportunistic infections. A growing body of literature demonstrates
that pathogenic variants in heterozygous state, may contribute to generation of autoantibodies in
RAG1-related disease. Compound heterozygous RAG1 mutations have been identified in a family
with the combined immunodeficiency phenotype, autoimmune cytopenia and multiple autoantibodies,
including anti-IFNα antibodies. The mechanism for generation of these autoantibodies is unclear, and
may be attributed to underdeveloped thymus with decreased AIRE expression [92,93].
2.5.2. FAS/FASL
The cell surface death receptor (FAS) belongs to the TNF receptor superfamily (TNFRS). Interaction
of the FAS receptor with its ligand FASL plays a central role in programmed cell death, also called
apoptosis. Autosomal dominant mutations of FAS or FASL genes result in decreased expression
of FAS and FASL proteins and failure to remove autoreactive cells [110,147]. Defective FAS-FASL
apoptotic pathway leads to a lymphoproliferative syndrome with autoimmune features (autoimmune
lymphoproliferative syndrome; ALPS; OMIM 601859). Enlargement of the lymph nodes, spleen
and/or liver with autoimmune cytopenia are the main features of the disease in most cases. In a
cohort of 75 patients with SLE, a heterozygous 84-bp in frame deletion in the FASL gene was detected
in a 64-year-old male [94]. His SLE manifestations include malar rash, arthritis, serositis, renal
disease, leukopenia, anti-DNA antibodies, and a positive ANA with generalized lymphadenopathy.
Polymorphisms in FAS and FASL genes were shown to increase SLE susceptibility [95,147].
2.5.3. RASopathies
RASopathies, which are caused by dominantly inherited mutations in several genes (KRAS, NRAS,
PTPN11, RAF, SHOC2 and SOS1), are a group of neurodevelopmental disorders including Noonan
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syndrome (NS; OMIM 163950) and Noonan-related syndromes (NS2-11; OMIM 605275, 609942, 610733,
611553, 613224, 613706, 615355, 616559, 616564, 618499). Beside classical phenotype patients with
these disorders may present with features of SLE, autoimmune thyroiditis, vitiligo, celiac disease
and Degos [79,145]. The affected proteins participate in the RAS/MAPK pathway that is involved in
regulation of different cellular processes by transduction of growth factor signals [145]. Shared cardinal
characteristics of the RASopathies include short stature, craniofacial malformations, webbed neck,
cardiac malformation, variable cognitive delay and an increased risk of cancer development [80,81].
Twelve patients with NS/Noonan-related syndrome phenotype and SLE characteristics have been
described to date [80–91]. Of these 12 patients, four had SHOC2 mutations, two had KRAS and
one had a PTPN11 mutation [80,81,84–86,90,91]. The remaining five patients with RASopathy and
SLE are molecularly undiagnosed [82,83,87–89]. Overall, the most frequently reported manifestation
associated with SLE was arthritis (n = 8/11), followed by pericarditis/pleuritis (n = 7/11), autoimmune
cytopenia (6/11), and skin involvement (n = 2/8). Compared to the classical SLE, male preponderance
(F:M = 1/2), a lower rate of skin involvement and a higher rate of serositis are noteworthy in patients
with RASopathies.
2.5.4. RELopathies
Patients with mutations in genes that regulate canonical NF-kB pathway can also present with
SLE and other autoimmune phenotypes. The A20 protein, encoded by the TNFAIP3 gene, is a
key negative regulator of NF-kB, NLRP3 inflammasome and other immune signaling pathways.
Dominantly inherited loss-of-function mutations in TNFAIP3 lead to early-onset autoinflammatory
disease haploinsufficiency of A20 (HA20; OMIM 616744). A patient with p.Phe224Serfs*4 mutation
was initially diagnosed with SLE, including central nervous system (CNS) vasculitis [96,97]. Another
study showed that patients with HA20 gradually progress to develop strong autoimmune features [98].
The autoimmune features may be attributed to a Type I interferon signature detected in peripheral blood
of these patients among other highly elevated proinflammatory cytokines [99]. Haploinsufficiency
of A20 was also identified in patients with childhood-onset autoimmune diseases and autoimmune
lymphoproliferative syndrome (ALPS; OMIM 601859) [100].
2.5.5. Deficiency of ADA2 (DADA2)
DADA2 (OMIM 615688) is caused by biallelic loss of function mutations in adenosine deaminase
2 (ADA2) gene, with a function of extracellular deaminase and growth factor. DADA2 patients have
broad disease spectrum including systemic vasculitis, strokes, livedoid rash, early-onset polyarteritis
nodosa (PAN), CVID and bone marrow failure. SLE-like phenotype and an elevated interferon gene
expression signature has been reported in same cases [101,102].
2.5.6. IKZF1
IKZF1 gene encodes the IKAROS protein, which is an important transcriptional factor in the process
of hematopoiesis. Heterozygous germline mutations in IKZF1 cause abnormal hematopoiesis, combined
variable immunodeficiency (CVID) and features of autoimmunity. SLE-like and immune thrombocytopenic
purpura (ITP) phenotypes have been reported in some patients [103,104]. A genome-wide association
study showed that the variant rs1456896 in the 5′ UTR of IKZF1 was relevant to lupus nephritis [105].
3. Conclusions
In the light of these observations, genetic analysis for monogenic lupus should be warranted
in patients with lupus phenotype and at least one of the following clinical features: early-onset
manifestations (<5 years), parental consanguinity, presence of family history for autoimmune diseases
in a first-degree relative. Whether all the genes discussed in this review should be included in the
targeted gene sequencing panel is questionable, however considering a continuum of clinical features
in patients with immune dysregulation and reasonable cost of NGS based sequencing this is feasible.
J. Clin. Med. 2020, 9, 712 12 of 20
Molecular diagnosis has become increasable valuable to guide patient management from diagnosis to
treatment strategies and has helped to define a spectrum of phenotypes linked to pathogenic variants
in a single gene.
Complement deficiencies are the most frequent subcategory of monogenic lupus. The second leading
cause of monogenic lupus are primary intereferonopathies. The frequency of clinical manifestations
in patients with monogenic SLE differs from multifactorial/polygenic SLE, with the majority of cases
having CNS disease and cutaneous manifestations, particularly chilblain lesions. Due to the overlapping
clinical manifestations, a multidisciplinary team approach including a rheumatologist, dermatologist,
neurologist and immunologist, is required for appropriate diagnosis and management of these genetically
and clinically heterogeneous diseases.
Given the complexity of regulation in the interferon signaling pathway, the recognition of novel
mendelian diseases of monogenic lupus will likely increase with the aid of whole exome (WES) and
whole genome (WGS) sequencing. These reverse genetic approaches will lead to identification of novel
genes linked to SLE and other autoimmune diseases, which will pave the way for the development of
new therapeutic options. Revisiting existing diagnostic criteria will be needed for the classification of
monogenic lupus and type I interferonopathies after elucidation of these molecular pathways and
recognition of overlapping manifestations. Revealing all pathogenetic pathways and recognizing the
clinical spectrum of monogenic SLE will not provide tailored therapy options only for this type of
inherited lupus but also to the classical multifactorial form of the SLE.
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